Corporate Presentation Corporate Presentation - May 2022 UPLOADED: May 10, 2022 Gutierrez AA. Clinical activity and immunogenicity of a neoantigen immunotherapy in non-small cell lung cancer. Neoantigen Based Therapies Summit. Weaponizing Vaccines and Cell Based Immunotherapies. October 28, 2021. Virtual Meeting UPLOADED: October 28, 2021 Gutierrez AA. Can neoantigen immunotherapies reverse resistance to PD-1 inhibitors and progression in NSCLC?. Non-Small Cell Lung Cancer Drug Development Summit. Virtual meeting. July 15, 2021 UPLOADED: July 15, 2021 Haigentz M, et.al. A phase 1 study of an off the shelf, multi-neoantigen vector (ADXS-503) in patients with metastatic non-small cell lung cancer (NSCLC) progression on pembrolizumab as last therapy. 2021 ASCO Annual meeting. June 4-8, 2021. Abst # 2616 UPLOADED: June 4, 2021 Monhanram V, et.al. Evaluation of total PD-1 expression using multi-color flow cytometry in metastatic non-small Cell lung cancer patients treated with multi-neoantigen vector (ADXS-503) alone and in combination of pembrolizumab to assess T-cell & T-cell UPLOADED: March 26, 2021 IO 360 Presentation UPLOADED: February 27, 2020 Immuno-Oncology 360° Conference Presentation UPLOADED: February 6, 2019
